Sinopia Biosciences is a San Diego based computational drug discovery company leveraging its proprietary machine learning platform to improve life changing therapeutics. Sinopia’s lead compound (SB-0107) is a patent protected small molecule with well-established favorable safety profile that significantly potentiates levodopa to treat Parkinson’s disease (PD), without exacerbating its main side effect, levodopa-induced dyskinesia (LID). SB-0107 shows consistent and unparalleled pre-clinical efficacy in highly translatable rodent models of PD motor symptoms across multiple studies in both acute and chronic treatments, as well as in a single patient observational study. SB-0107's unique mechanism of action allows combination use with low dose levodopa to achieve high potency with no dyskinesia in rodents. Sinopia is planning to complete a proof-of-concept study with SB-0107 in Parkinson's disease patients in a Phase Ib/IIa clinical study.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):